Fierce Biotech News & Reports
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
Introducing Fierce Biotech's 2024 Fierce 15
One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...
Fierce Biotech Layoff Tracker 2024
5 days ago · March—18 companies. March 29 - Mustang Bio: Cell therapy-focused Mustang has laid off an undisclosed number of workers. The company declined to disclose how many employees would be impacted ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for chronic weight ...
Notable goes bankrupt, ending plans for Boehringer cancer drug
Oct 15, 2024 · Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.. Notable's ...
Boehringer inks $607M Circle pact for preclinical cancer program
Oct 9, 2024 · Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package potentially worth up to $607 million to secure the rights to a ...
FDA approves Exact Sciences’ next-gen Cologuard Plus home test
Oct 4, 2024 · Ten years after first collecting an FDA approval, it’s time for version number two. Exact Sciences has received an agency green light for Cologuard Plus, the next generation of its mainstay, at ...
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 · Daiichi began enrolling SCLC patients in a phase 3 trial of its B7-H3-directed ADC in May. The candidate demonstrated its potential in a study that linked the phase 3 dose to a 54.8% response rate ...
FDA adcomm ends in favor of Stealth's Barth syndrome drug
Oct 10, 2024 · On Oct. 8, the FDA released briefing documents ahead of the vote arguing that Stealth’s data package likely isn’t enough to snare approval, even via an accelerated pathway. The agency ...
Cytovale gains momentum with $100M for its sepsis screening test
Oct 10, 2024 · Cytovale aims for its test to become as ubiquitous as urgent blood troponin screening for detecting heart attacks and cardiac damage, or CT scans for diagnosing strokes—while sepsis is more ...